Sonolisib

DB12601InvestigationalSmall molecule

Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.

Formula / weight: C₂₉H₃₅NO₈ · 525.598 g/mol (avg)
Code names: PX-866

Resolves to

Compound

UNII987796874TCAS502632-66-8ChEMBLCHEMBL411907ChEBI65345PubChem9849735

Structure

InChIKeyQIUASFSNWYMDFS-NILGECQDSA-NSMILESCOC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(C)=O)[C@@]12C

Targets

P48736PIK3CG

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Sonolisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account